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Abstract: This article provides an overview of the obstetric and gynecological manifestations 
of Crohn’s disease (CD). High incidence of the new onset of the disease in young women in 
their reproductive years demands special concern from physicians involved in their treatment. 
Pregnant women with CD are considered high-risk patients, regardless of disease activity index, 
due to associated complications. Predominately described complications are premature birth, 
low birth weight, and congenital anomalies. To minimize the risk for adverse pregnancy/birth 
outcomes, it is recommended that remission be achieved before conception. Treatment of CD 
in pregnant women is similar to that among the nonpregnant population, and there is no valid 
reason to terminate it, since most of the drugs are proven to be safe. Women with CD who wish 
to conceive or are already pregnant need to be properly advised according to the newest guide-
lines on the subject, given by the European Crohn’s and Colitis Organization. Gynecological 
manifestations are another special feature of CD. They are important in that they may facilitate 
early recognition of the underlying disease, which usually stays unrecognized for years before 
intestinal manifestation; in this way, the underlying manifestations are often mistreated.
Keywords: adverse pregnancy outcome, Crohn’s disease, gynecological complications, immu-
nosuppressive therapy
Introduction
Crohn’s disease (CD) is a chronic inflammatory disease characterized by the tendency 
of chronic or relapsing activation of the immune system within the gastrointestinal 
(GI) tract. Although CD primarily affects the alimentary tract from the mouth to the 
anus, there are numerous extraintestinal manifestations (EIMs).
The disease usually begins within the alimentary tract, with a propensity for devel-
oping in the distal small bowel and proximal large bowel. Due to its subtle clinical 
presentation, a long delay between the onset of the disease and its diagnosis is common. 
Early features usually include diarrhea, fever, weight loss, and abdominal pain.
The incidence rates of CD vary between 0.1–20.2 per 100,000 person-years, most 
likely due to genetic and environmental factors.1 The highest reported incidence rate 
of inflammatory bowel disease (IBD) to date was found on the Faroe Islands (81.5 per 
100,000 person-years).2
Higher incidence rates have been noted in more northern latitudes, although the 
north–south gradient is now less than previously observed. Recent years have seen 
changes in the classical geographical distribution of the disease, and we are witness-
ing rising incidence and prevalence rates in traditionally low-incident regions such 
as Asia, South America, and southern and eastern Europe.2 Now, it is worthwhile to 
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investigate the west–east gradient regarding IBD occurrence 
in Europe.2
A specific feature of CD is that it holds the possibility 
for the development of EIMs of the disease.3 They occur 
in almost one-third (21%–41%) of all patients with CD, 
depending on the patient population and the criteria used to 
identify them. Commonly, the number of these manifesta-
tions increases with the duration of the disease. In a cohort 
of 480 patients followed from the time of diagnosis, it was 
observed that the cumulative probability of inflammatory 
EIMs varied from 22% at diagnosis to 40% at 10 years after 
diagnosis.4
Among others, fistulization is a frequent complication 
of longstanding disease. Special attention has to be paid to 
women due to the possibility that fistulization may occur 
in the genitourinary tract, which can cause vulvovaginal, 
perianal, perineal, or urological symptoms. Due to the 
predilection of CD for young women of reproductive age, 
it can cause substantial disturbances in reproductive func-
tion. Thus, it is important that gynecologists understand the 
mechanisms and possible complications of CD. This review 
provides an overview of the obstetric and gynecological 
manifestations of CD.
Obstetrics
CD affects women in their peak reproductive years  (Figure 1).5 
Approximately 50% of patients are under 35 years of age at 
the time of the initial diagnosis, and 25% of them conceive 
for the first time during that period.6
Newer studies showed that women with inactive CD 
have similar fertility rates as the general population.7 
However, fertility is reduced in women with active CD 
and during the postsurgery period.8 Infertility caused by 
surgical treatment may be due to adhesions in the pelvis after 
the surgery, as well as by fallopian tube occlusion.9 Apart 
from the effects of the disease itself (anemia, fatigue, and 
flatulence), libido and sexual activity can be influenced and 
reduced by a distorted body image.10 Increased voluntary 
childlessness is also noticed in this group of patients.11 The 
main reason behind this seems to be misconception and 
fear that an adverse pregnancy outcome is likely to occur, 
and this belief is often not justified.12 A knowledge assess-
ment tool was designed to assess the knowledge of women 
with CD about the possible outcomes of their pregnancies. 
This measure is named the Crohn’s and Colitis Pregnancy 
Knowledge Score (CCPKnow). The findings from studies 
using this measure showed that nearly half of the women 
demonstrated poor results on the test, and more than one-
third of them believed that IBD treatment during pregnancy 
is harmful to their unborn child.13,14 These negative findings 
lead to the conclusion that patients need to be better informed 
to avoid unnecessary complications, especially regarding 
treatment of the disease.
The risk for an adverse birth outcome depends on many 
factors that should be taken into consideration among preg-
nant women with CD. Some of these factors are general, such 
as parity, mother’s age at the time of delivery, gestational 
age, and smoking during pregnancy, and some are directly 
connected to the mother’s underlying disease like the disease 
activity index, anti-inflammatory drug therapy used during 
pregnancy, and disease duration.15
It is recommended that pregnant women with CD are 
routinely considered as a high-risk group of patients, 
regardless of disease activity.16,17 Women with quiescent 
CD at the time of conception have the same risk for 
adverse pregnancy outcomes as the general population.6 
It is considered that active disease at the time of conception, 
or relapse during pregnancy, increases the risk for adverse 
pregnancy outcomes.18 If pregnancy occurs at a time of 
active disease, two-thirds of patients may have persistent 
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Figure 1 Incidence of Crohn’s disease in women by age.
Note: Copyright © 2008 Nature Publishing Group. Reproduced with permission from Herrinton LJ, Liu L, Lewis JD, et al. Incidence and prevalence of inflammatory bowel 
disease in a Northern California managed care organization, 1996–2002. Am J Gastroenterol. 2008;103(8):1998–2006.5
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activity during pregnancy and, of these, two-thirds may 
deteriorate;19 this is known as “the rule of thirds.”6 This 
statement specifically refers to pregnant women with active 
CD in comparison with pregnant women with ulcerative 
colitis (UC).6,20,21 The primary aim of preconception coun-
seling should be to achieve remission of disease activity for 
at least 3 months before conception, especially if we keep 
in mind that the disease state during conception usually 
tends to remain throughout the pregnancy.22 The first and, so 
far, only prospective study (by Bortoli et al23) showed that 
there was no significant difference in pregnancy outcomes 
between pregnant women with IBD and healthy controls. 
It is important to emphasize that 88% of pregnant women 
in this study had quiescent disease.
Pregnancy outcomes
The mechanisms behind the pathophysiology of adverse 
pregnancy outcomes are not yet completely determined. 
They appear to be mainly associated with the nature of the 
disease itself, the disease activity index, anti-inflammatory 
drug therapy during pregnancy and, in some cases, with 
the child’s genetic susceptibility to CD.15,24 Some of the 
assumed pathophysiological mechanisms include increased 
intestinal permeability, vascular abnormalities, infectious 
agents, abnormal immunological response, production of 
autoantibodies, and proinflammatory molecules, which 
can all lead to malnutrition that is not so rare in patients 
with CD.15 There is a hypothesis that increased levels of 
prostaglandins during flares of inflammation can provoke 
premature contractions of the smooth muscles in the uterus, 
causing premature birth.25
Premature birth, low birth weight (LBW), and con-
genital anomalies (CA) are the most common complications 
observed by the majority of studies.26,27 Stillbirth and a need 
for Cesarean section seem to be less common. Premature 
birth is defined as birth before 37 weeks of gestation, and 
LBW is defined as weight under 2,500 g.25 In most studies, 
the exact definition of LBW remains unclear because it can 
be seen in premature newborns, newborns with intrauterine 
growth retardation born at term, and newborns with LBW 
for genetic reasons. CA are described in terms that do not 
distinguish between minor and major anomalies. A Danish 
study found no increased risk for overall CA in pregnant 
women with CD, but instead found an increased risk for 
specific anomalies like limb deficiency, urinary tract defects, 
and multiple malformations.15 These findings refer to birth 
outcomes in pregnant women with UC rather than those 
with CD.28
Other rare complications include stillbirth, and some 
other conditions which can influence decision about the 
mode of delivery.25 The choice of the mode of delivery is 
closely connected to the clinical appearance of the disease. 
Studies conducted in the past have shown an increased rate 
of Cesarean section in pregnant women with CD, because it 
was considered that vaginal delivery and episiotomy could 
be the main reasons for relapse or de novo involvement 
of perianal disease.29 The progression of perianal disease 
was found to be less frequent after vaginal delivery when 
compared to Cesarean section, which diminishes Cesarean 
section assumed protective role.30 The general opinion is 
that decisions about Cesarean section should be based on 
obstetric indications. There are only two gastroenterological 
indications for Cesarean section: active perianal disease and 
the presence of an ileoanal pouch.7 In the first case, vaginal 
delivery and episiotomy can aggravate the existing condi-
tion, causing anal sphincter dysfunction.31
The effects of pregnancy on CD can be observed during 
the pregnancy itself and during the postpartum period.32 
Disease activity is the same in pregnant women with CD as 
in nonpregnant women, which means that pregnancy does 
not represent an independent risk factor for increased flare 
rates.33 A retrospective study even suggests that the disease 
activity index slightly decreases during pregnancy, as com-
pared to the years preceding and following the pregnancy.34 
This phenomenon could be explained by reduced tobacco 
consumption during pregnancy, or due to more aggressive 
drug treatments used in accordance to the recommendations 
established to maintain remission in pregnant women.34,35 
Pregnancy does not impact on disease phenotype or resec-
tion rates.35 A comparison of the influence of pregnancy on 
the overall course of IBD and the need for surgical treatment 
showed a significant difference between multiparous and 
nulliparous women. Multiparous women had a lower rate 
of relapse at 3 years postpartum.35,36 The need for surgical 
treatment was reduced, and the interval between surgical 
interventions was prolonged.37 Some theories suggest that 
this phenomenon can be explained by the disparity between 
the mother’s and fetus’s class 2 human leukocyte antigen.38 
Paternal antigens in the fetus induce a protective downregu-
lation in the maternal immune system that results in a more 
benign form of the disease after pregnancy than was evident 
before the pregnancy.
Pharmacotherapy
The pharmacotherapy used during pregnancy is important 
to treat active disease, to maintain remission, and to treat 
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flare-ups during pregnancy. Anti-inflammatory and immuno-
modulatory therapies for CD have possible teratogenic and 
mutagenic effects. Teratogenic effects affect the development 
of a normal embryo and fetus, and these effects are dependent 
on dosage; conversely, mutagenic effects are most likely 
caused by mutations that occur during deoxyribonucleic acid 
synthesis in sperm, and these mutations are subsequently 
transferred by the father.15 This is the reason why detailed 
studies have been performed on the safety of drug therapy 
in pregnant women.
Some of the most relevant groups of drugs used dur-
ing pregnancy include aminosalicylates, corticosteroids, 
azathioprine/6-mercaptopurine (AZA/6-MP), and antibodies 
against tumor necrosis factor (anti-TNF). Antibiotics are 
used predominantly in the management of perianal disease; 
methotrexate is contraindicated during pregnancy.7 Among 
aminosalicylates, studies conducted in the past considered 
sulphasalazine to be teratogenic, but newer population-based 
studies have shown lower rates of adverse outcomes in preg-
nant women with IBD than those in the general population after 
sulphasalazine therapy.39–42 The same findings and conclusions 
can be applied to mesalazine use during pregnancy.43–45
Corticosteroids cross the placental barrier and are consid-
ered to have possible adverse effects on fetal development. In 
a meta-analysis of ten cohort and case control studies, there 
were no increased risks of overall congenital abnormalities, 
but the researchers found a higher risk of oral clefts; the study 
was conducted on non-IBD women.46 One prospective study 
did not find an increased risk of overall congenital abnormali-
ties, nor did the authors find an increased risk of oral clefts 
in pregnant women taking corticosteroids.47 The European 
Crohn’s and Colitis Organization’s (ECCO) guidelines 
regarding therapy during pregnancy mention that although 
corticosteroids cross the placental barrier, they are converted 
into less active metabolites, so in fetal blood, they can be 
found only in low concentrations.17 This is the reason why 
their usage is not prohibited during pregnancy. The effects 
of AZA and its metabolite, 6-MP, are mostly observed in 
transplant and rheumatology cohorts.17 They are placed in 
category D of drugs for use during pregnancy (there is  positive 
evidence of human fetal risk based on adverse reaction data 
from investigational or marketing experience – or from studies 
conducted on humans – but the potential benefits may war-
rant use of the drug in pregnant women despite the potential 
risks associated with this treatment), as  categorized by the 
United States Food and Drug Administration.48 A  Danish 
study found an increased risk of preterm birth, perinatal 
mortality, and increased risk of CA in women who were 
on therapy with AZA/6-MP during pregnancy.49 The CA 
associated with thiopurine therapy in pregnant women with 
CD included congenital cataracts, occipital encephalocele, 
and CA of the sternocleidomastoid and skin. The study was 
conducted by comparing a small number of pregnant women 
with IBD on thiopurine therapy with the general population, 
so the role of the disease itself remains unclear. A recent 
retrospective study by Casanova et al50 focused on the safety 
of thiopurine and anti-TNF therapy during pregnancy. The 
authors were searching for different obstetric complications 
in the mother and the newborn that they could connect to the 
therapy, and described them in terms of unfavorable Global 
Pregnancy Outcome. The conclusion was that treatment 
with thiopurines is the only predictor of favorable Global 
Pregnancy Outcome, as compared to pregnant women who 
were not exposed to thiopurine therapy, and to those receiv-
ing anti-TNF treatments. Other studies did not confirm the 
increased risk of adverse birth outcomes, so the ECCO guide-
lines consider these treatments to be safe forms of therapy in 
pregnant women with IBD.51–54
TNF-α is a proinflammatory cytokine that plays an 
important role in IBD and during the pregnancy.51–53 Anti-
TNF drugs are effective for achieving and maintaining 
remission in moderate or severe IBD that is refractory to 
conventional therapy. However, these drugs cross the placen-
tal barrier, and the question that imposes is how they affect 
the fetus and its development. Among the anti-TNF agents, 
the effect of the infliximab (IFX) is the most studied. It is 
important to know that IFX crosses the placenta in the second 
and third trimesters. If it is used after the second trimester, 
it remains in the newborn’s system for up to 6 months after 
delivery, which increases the risk of newborn infections.54,55 
Two large studies conducted on pregnant women on IFX 
therapy showed no increase in adverse outcomes such as 
congenital malformation, miscarriage, or neonatal complica-
tions when compared with IFX-naïve pregnant women.56,57 
Adalimumab levels can also be detected in the cord and in 
the infant after delivery, and this is why the recommendation 
for the discontinuation of therapy with anti-TNF agents is 
the same for both of these drugs. Certolizumab pegol is a 
polyethylene glycosylated Fab’ fragment of a humanized 
TNF inhibitor monoclonal antibody. It crosses the placenta 
in the first trimester during organogenesis, but its levels in 
the cord and in the infant after delivery are low.55 The latest 
systematic literature reviews agree on the opinion that IFX 
and adalimumab therapy is acceptable during conception, 
and that the therapy should be stopped at least by the end 
of the second trimester.54,58
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To conclude, there are a growing number of studies and 
evidence to date that support the standpoint that there is no 
need to terminate therapy in pregnant women with IBD.59 
Most of the drugs have been proven to be safe, and it is 
considered that the alternative of higher disease activity can 
cause much greater problems than the therapy itself.7,33
Gynecology
CD is linked to specific complications in women’s genitouri-
nary tracts. These complications require special attention and 
collaboration between gynecologists and gastroenterologists 
because, in most cases, they are difficult to manage and affect 
a woman’s reproductive and psychosocial health. Some of 
these complications include vulvovaginal disease, perianal 
disease, and rectovaginal and enterovesical fistulas.
Clinical manifestations
One of the manifestations of CD in the genitourinary tract is 
described as non-caseating granulomatous inflammation of 
the skin. More than half of the registered lesions are presented 
in the vulvar region.22,60 A variety of clinical manifestations 
is described in that area such as unilateral edema, erythema, 
papule and nodule lesions, ulcerations, vulvar pruritus, 
and pain.61 The classic lesion is known as “knife-like”, and it 
is predominately located in the skin-fold region.62 The most 
frequent lesion seen in women with CD is genital swelling 
with or without erythema, which occurs in 60% of cases, and 
is accompanied by perianal disease, especially in children.61,62 
There is a difference in the time of presentation between 
adults and children. In adults, it usually occurs after the 
initial diagnosis, and in children, it occurs at the same time 
or even prior to the initial diagnosis of CD. Approximately 
25% of vulvar lesions are recognized before GI symptoms 
appear.60 It is important to emphasize the significance of these 
statements because differential diagnoses of vulvovaginal 
lesions can represent the critical point for early recognition 
and intervention in non-recognized CD patients.
CD is often complicated by perianal manifestations.63 It is 
considered that the incidence of these manifestations increases 
the more distal the involvement of the GI tract is, and the 
incidence rate ranges from 12% in patients with ileal disease 
to 92% in those with rectal and colonic disease. Up to 40% of 
patients will develop perianal manifestations before the other 
GI symptoms appear;64 perianal fistulas can precede the diag-
nosis of CD by several years.65 Women are more likely to seek 
help from their gynecologists than from a  gastroenterologist 
because they experience symptoms of perianal or perineal 
discomfort.64 The most common findings in the perianal 
region are abscesses and fistulas, and the less common ones 
are fissures and anal ulcers.66,67 The medical approach should 
recognize perianal fistulizing CD as a distinct disease pheno-
type from luminal fistulizing disease, because of the aggressive 
and chronic behavior of the perianal lesions.68,69
Treatment
Women with CD can develop specific complications due to 
the anatomy of their genitourinary tracts, including the pres-
ence of rectovaginal and enterovesical fistulas. Data suggest 
that 10% of women could develop rectovaginal fistulas, which 
represents an important risk factor for the development of 
mucinous adenocarcinomas.70–72
The treatment of special gynecological manifestations 
usually includes a combination of medical and surgical 
treatments, depending on the type and severity of the clini-
cal appearance. If recognized in time, vulvovaginal disease 
is treated with systemic therapy for CD, and antibiotics are 
added in case of secondary infection. Surgery should be con-
sidered only in rare cases of failure of medical therapy.22 The 
treatment of perianal fistulas depends on the symptoms and 
complexity of fistulas. Abscesses must always be ruled out, 
because they require immediate drainage. ECCO guidelines 
recommend antibiotics, metronidazole or ciprofloxacin, as 
first-line conventional therapy in combination with second-
line AZA/6-MP. Anti-TNF agents are still a third-line therapy, 
which are used in combination with antibiotics, thiopurine 
therapy, and surgical treatment. The sequence of each therapy 
is not strictly determined.17 The treatment of rectovaginal 
fistulas with medical treatment alone often fails, which is 
why the recommendation is to combine medical and surgical 
treatments to achieve better rates of success.22
Crohn’s disease and the menstrual 
cycle
The other important physiological condition that physicians 
have to bear in mind is the menstrual cycle. The significance 
of the menstrual cycle in female patients with CD lies in 
recognizing alterations in GI symptoms that are influenced 
by hormonal changes, and distinguishing them from true 
exacerbations of the disease. Lim et al73 conducted the first 
prospective study that investigated the connection between 
the menstrual cycle and GI symptoms in women with IBD. 
The authors divided GI symptoms into non-IBD-specific and 
IBD-specific categories. Non-IBD-specific GI symptoms 
included nausea, abdominal discomfort/pain, flatulence, 
tenesmus, diarrhea, and constipation, and they seemed to 
be similar to those present in the general healthy popula-
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tion during the premenstrual/menstrual phase. IBD-specific 
symptoms referred to nocturnal diarrhea, hematochezia, and 
fecal incontinence. Systemic menstrual symptoms included 
headache, anxiety, depression, acne, edema, urinary fre-
quency, and mastalgia.
The results of this study also showed increased frequency 
and severity of premenstrual symptoms in women with IBD 
compared with the general healthy population.73 The findings 
especially referred to nausea, abdominal pain, flatulence, and 
tenesmus, while the incidence of other symptoms was not 
significantly increased. In addition, IBD patients had a higher 
number of stools, loose stools, and more severe abdominal 
pain across all of the menstrual phases. The difference in 
incidence in IBD-specific symptoms observed among dif-
ferent menstrual phases was found not to be significantly 
altered, leading to the conclusion that changes in hormone 
status during the menstrual cycle do not influence the patho-
logical mechanism of the disease itself. The exact pathway 
through which gonadal hormones affect GI changes remains 
unclear, and is mostly based on presumptions. It is known 
that serotonin is ubiquitous in the GI tract and that it plays 
a key role in motor sensory function.74,75 Since estrogen and 
progesterone influence the serotonergic system in the brain 
by increasing its availability, some studies have used this 
connection to explain disturbances in the GI tract during 
the premenstrual and menstrual phases.76 Prostaglandin also 
interferes with the physiology of the GI system,77,78 and it is 
thought to be the main cause of looser stools, as it inhibits 
transepithelial ion transport in the small intestine.79 Most 
of these studies were conducted predominately in patients 
with UC and IBS, which is why it is not possible to draw 
conclusions about the exact way in which hormonal changes 
during the premenstrual and menstrual phases affect women 
with CD.
The reversed situation – how CD affects women’s 
 menstrual cycles – has also been investigated. Sides et al22 
found that the onset of the disease before or during pregnancy 
could result with a delayed menarche. In adult women, the 
main problem seems to be irregular menses; oligomenorrhea 
is the most common abnormality.80 All of these problems are 
secondary to the underlying disease and appear as a result of 
poor nutrition, low body fat index, chronic inflammation, and 
the physiological stress of the disease.22
Conclusion
This article provides an overview of the specific features of 
CD in women. CD is a chronic inflammatory disease with 
a rising prevalence rate observed throughout the world, and 
it features a high incidence rate in women in their peak 
reproductive years.
Fertility rates in women with inactive CD are similar to 
those of the general population. It is important to properly 
advise patients according to the newest findings, to reduce 
increased rates of voluntary childlessness and to prevent 
unnecessary complications in pregnancy. Women with qui-
escent disease at the time of conception have a similar risk 
for experiencing adverse pregnancy outcomes as the healthy 
population, while active disease at conception or relapse dur-
ing pregnancy increases the possibility of adverse pregnancy 
outcomes. Preconception counseling should involve both 
obstetricians and gastroenterologists, and the aim should be 
to achieve remission at least 3 months before conception. 
The type of pharmacotherapy used for treating active disease 
and for maintaining remission in pregnant women with CD 
does not differ from standard therapy in other groups of 
patients. The fear that drugs would lead to adverse effects 
during the course of pregnancy has led to detailed studies that 
have been performed regarding the safety of drug therapy 
among pregnant women. So far, most of these drugs have 
been shown to be safe, and the newest ECCO guidelines 
advise that there is no need to terminate therapy in pregnant 
women. The opinion is that the alternative of higher disease 
activity can cause much greater problems than the therapy 
itself. Physicians have to be aware of the recommendations 
and limitations for each type of drug because, despite the 
guidelines, pregnant women with CD have to be treated as 
a high-risk group of patients that needs special attention 
regardless of disease activity.
Abnormalities of the menstrual cycle have been observed 
in these patients, and it was noticed that some symptoms 
of CD are closely connected to hormonal changes; specifi-
cally, during the menstrual cycle, these symptoms can be 
emphasized. It is important to distinguish between these 
abnormalities and true flares of the disease. An awareness of 
these special features of CD in women can lead to a reduced 
number of complications and their adequate treatment.
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